MedTrace Logo

Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy

NCT03515356 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-03-09

No results posted yet for this study

Summary

This randomized, controlled, pilot experiment will evaluate the effects of an aerobic walking intervention on OIPN (oxaliplatin-induced peripheral neuropathy) in patients with gastrointestinal (GI) cancer who are already prescribed oxaliplatin (85 mg/m2 every other week for at least six cycles) by their oncologists. Oxaliplatin is a standard chemotherapy treatment for invasive GI cancers that causes OIPN in 85-95% of patients.

Conditions

Interventions

BEHAVIORAL

MI-Walk Intervention

Eight-week motivational enhancement therapy and home-based aerobic walking intervention

BEHAVIORAL

Physical Activity Education Pamphlet

Physical activity education pamphlet only

Sponsors & Collaborators

  • Unity Health Toronto

    collaborator OTHER

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Grace Kanzawa-Lee, BSN, RN · University of Michigan School of Nursing

  • Ellen M Lavoie Smith, PhD · University of Michigan School of Nursing

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2019-06-24
Completion
2019-06-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515356 on ClinicalTrials.gov